{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T05:55:08Z","timestamp":1773381308108,"version":"3.50.1"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism Reports"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.ymgmr.2026.101293","type":"journal-article","created":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T20:07:37Z","timestamp":1770840457000},"page":"101293","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Olipudase alfa treatment for pediatric acid sphingomyelinase deficiency in Egypt: A prospective, observational cohort study with an interventional subgroup"],"prefix":"10.1016","volume":"46","author":[{"given":"Nehal Abdelaziz","family":"Arafa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aml","family":"Mahfouz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shimaa","family":"Anwar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iman","family":"Marzouk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgmr.2026.101293_bb0005","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s13023-017-0572-x","article-title":"Disease manifestations and burden of illness in patients with acid sphingomyelinase deficiency (ASMD)","volume":"12","author":"McGovern","year":"2017","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgmr.2026.101293_bb0010","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1007\/s10545-007-0632-9","article-title":"The pathogenesis and treatment of acid sphingomyelinase-deficient Niemann-Pick disease","volume":"30","author":"Schuchman","year":"2007","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgmr.2026.101293_bb0015","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/BF01247328","article-title":"Deletion of arginine (608) in acid sphingomyelinase is the prevalent mutation among Niemann-Pick disease type B patients from northern Africa","volume":"92","author":"Vanier","year":"1993","journal-title":"Hum. Genet."},{"key":"10.1016\/j.ymgmr.2026.101293_bb0020","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/sj.ejhg.5201044","article-title":"Prevalence of lysosomal storage diseases in Portugal","volume":"12","author":"Pinto","year":"2004","journal-title":"Eur. J. Hum. Genet."},{"key":"10.1016\/j.ymgmr.2026.101293_bb0025","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.beem.2014.08.004","article-title":"Epidemiology and diagnosis of lysosomal storage disorders; challenges of screening","volume":"29","author":"Kingma","year":"2015","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ymgmr.2026.101293_bb0030","first-page":"100344","article-title":"Prevalence of lysosomal storage disorders in Australia from 2009 to 2020","volume":"19","author":"Chin","year":"2022","journal-title":"Lancet Reg. Health West Pac."},{"key":"10.1016\/j.ymgmr.2026.101293_bb0035","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s10545-010-9093-7","article-title":"The birth prevalence of lysosomal storage disorders in the Czech Republic: comparison with data in different populations","volume":"33","author":"Poupetova","year":"2010","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgmr.2026.101293_bb0040","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1212\/01.wnl.0000194208.08904.0c","article-title":"Natural history of type A Niemann-Pick disease: possible endpoints for therapeutic trials","volume":"66","author":"McGovern","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.ymgmr.2026.101293_bb0045","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1186\/s13023-024-03234-6","article-title":"ASSUR study group, Acid sphingomyelinase deficiency in France: a retrospective survival study","volume":"19","author":"Mauhin","year":"2024","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgmr.2026.101293_bb0050","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.ymgme.2012.06.015","article-title":"Acid sphingomyelinase (Asm) deficiency patients in the Netherlands and Belgium: disease spectrum and natural course in attenuated patients","volume":"107","author":"Hollak","year":"2012","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgmr.2026.101293_bb0055","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s10545-005-5671-5","article-title":"Acid sphingomyelinase deficiency. Phenotype variability with prevalence of intermediate phenotype in a series of twenty-five Czech and Slovak patients. A multi-approach study","volume":"28","author":"Pavlu-Pereira","year":"2005","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgmr.2026.101293_bb0060","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.jpeds.2006.06.034","article-title":"Acid sphingomyelinase deficiency: prevalence and characterization of an intermediate phenotype of Niemann-Pick disease","volume":"149","author":"Wasserstein","year":"2006","journal-title":"J. Pediatr."},{"key":"10.1016\/j.ymgmr.2026.101293_bb0065","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/gim.2017.7","article-title":"Consensus recommendation for a diagnostic guideline for acid sphingomyelinase deficiency","volume":"19","author":"McGovern","year":"2017","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgmr.2026.101293_bb0070","article-title":"Diagnostic odyssey for patients with acid sphingomyelinase deficiency (ASMD): exploring the potential indicators of diagnosis using quantitative and qualitative data","volume":"38","author":"Doerr","year":"2024","journal-title":"Mol. Genet. Metab. Rep."},{"key":"10.1016\/j.ymgmr.2026.101293_bb0075","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.beem.2014.08.005","article-title":"Non-neuronopathic lysosomal storage disorders: disease spectrum and treatments","volume":"29","author":"Pastores","year":"2015","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ymgmr.2026.101293_bb0080","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1096\/fj.00-0014com","article-title":"Infusion of recombinant human acid sphingomyelinase into Niemann-Pick disease mice leads to visceral, but not neurological, correction of the pathophysiology","volume":"14","author":"Miranda","year":"2000","journal-title":"FASEB J."},{"key":"10.1016\/j.ymgmr.2026.101293_bb0085","series-title":"Olipudase Alfa: First Approval Drugs","first-page":"941","volume":"82","author":"Keam","year":"2022"},{"key":"10.1016\/j.ymgmr.2026.101293_bb0090","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s40261-023-01270-x","article-title":"Olipudase alfa in non-CNS manifestations of acid sphingomyelinase deficiency: a profile of its use","volume":"43","author":"Syed","year":"2023","journal-title":"Clin. Drug Investig."},{"key":"10.1016\/j.ymgmr.2026.101293_bb0095","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1016\/j.gim.2022.03.021","article-title":"A randomized, placebo-controlled clinical trial evaluating olipudase alfa enzyme replacement therapy for chronic acid sphingomyelinase deficiency (ASMD) in adults: one-year results","volume":"24","author":"Wasserstein","year":"2022","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgmr.2026.101293_bb0100","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1186\/s13023-022-02587-0","article-title":"Long-term safety and clinical outcomes of olipudase alfa enzyme replacement therapy in pediatric patients with acid sphingomyelinase deficiency: two-year results","volume":"17","author":"Diaz","year":"2022","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgmr.2026.101293_bb0105","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1038\/s41436-021-01156-3","article-title":"One-year results of a clinical trial of olipudase alfa enzyme replacement therapy in pediatric patients with acid sphingomyelinase deficiency","volume":"23","author":"Diaz","year":"2021","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgmr.2026.101293_bb0110","article-title":"Enzyme replacement therapy for children with acid sphingomyelinase deficiency in the real world: A single center experience in Taiwan","volume":"34","author":"Pan","year":"2023","journal-title":"Mol. Genet. Metab. Rep."},{"key":"10.1016\/j.ymgmr.2026.101293_bb0115","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s40348-025-00199-9","article-title":"Outcome of enzyme replacement therapy for hematological and visceral manifestations in children with acid sphingomyelinase deficiency: a single center experience in upper Egypt","volume":"12","author":"Youssef","year":"2025","journal-title":"Mol. Cell Pediatr."},{"key":"10.1016\/j.ymgmr.2026.101293_bb0120","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s13023-024-03020-4","article-title":"Real-life impacts of olipudase alfa: the experience of patients and families taking an enzyme replacement therapy for acid sphingomyelinase deficiency","volume":"19","author":"Raebel","year":"2024","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgmr.2026.101293_bb0125","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1002\/humu.22981","article-title":"HGVS recommendations for the description of sequence variants: 2016 update","volume":"37","author":"den Dunnen","year":"2016","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.ymgmr.2026.101293_bb0130","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ymgme.2015.05.013","article-title":"Successful within-patient dose escalation of olipudase alfa in acid sphingomyelinase deficiency","volume":"116","author":"Wasserstein","year":"2015","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgmr.2026.101293_bb0135","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1136\/jmg.20.1.58","article-title":"Consanguineous matings in the Egyptian population","volume":"20","author":"Hafez","year":"1983","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.ymgmr.2026.101293_bb0140","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1067\/mpd.2003.113","article-title":"Growth restriction in children with type B Niemann-Pick disease","volume":"142","author":"Wasserstein","year":"2003","journal-title":"J. Pediatr."},{"key":"10.1016\/j.ymgmr.2026.101293_bb0145","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ymgme.2016.12.008","article-title":"Types A and B Niemann-Pick disease","volume":"120","author":"Schuchman","year":"2017","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgmr.2026.101293_bb0150","article-title":"Plasma lyso-sphingomyelin levels are positively associated with clinical severity in acid sphingomyelinase deficiency","volume":"28","author":"Breilyn","year":"2021","journal-title":"Mol. Genet. Metab. Rep."},{"key":"10.1016\/j.ymgmr.2026.101293_bb0155","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1186\/s13023-023-02797-0","article-title":"Screening for lysosomal diseases in a selected pediatric population: the case of Gaucher disease and acid sphingomyelinase deficiency","volume":"18","author":"Di Rocco","year":"2023","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgmr.2026.101293_bb0160","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1186\/s13256-018-1805-x","article-title":"Deep sequencing of SMPD1 gene revealed a heterozygous frameshift mutation (p.Ser192Alafs) in a Palestinian infant with Niemann-Pick disease type A: a case report","volume":"12","author":"Nasereddin","year":"2018","journal-title":"J. Med. Case Rep."},{"key":"10.1016\/j.ymgmr.2026.101293_bb0165","doi-asserted-by":"crossref","DOI":"10.12659\/AJCR.937220","article-title":"Compound heterozygote mutation in the SMPD1 gene leading to Nieman-Pick disease type A","volume":"23","author":"Kav\u010di\u010d","year":"2022","journal-title":"Am. J. Case Rep."},{"key":"10.1016\/j.ymgmr.2026.101293_bb0170","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s13023-019-1029-1","article-title":"Chronic visceral acid sphingomyelinase deficiency (Niemann-Pick disease type B) in 16 Polish patients: long-term follow-up","volume":"14","author":"Lipinski","year":"2019","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgmr.2026.101293_bb0175","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s13023-023-02686-6","article-title":"Consensus clinical management guidelines for acid sphingomyelinase deficiency (Niemann-Pick disease types A, B and A\/B)","volume":"18","author":"Geberhiwot","year":"2023","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgmr.2026.101293_bb0180","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1097\/PAS.0000000000000659","article-title":"Clearance of hepatic sphingomyelin by olipudase alfa is associated with improvement in lipid profiles in acid sphingomyelinase deficiency","volume":"40","author":"Thurberg","year":"2016","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.ymgmr.2026.101293_bb0185","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.ymgme.2020.06.010","article-title":"Long-term efficacy of olipudase alfa in adults with acid sphingomyelinase deficiency (ASMD): further clearance of hepatic sphingomyelin is associated with additional improvements in pro- and anti-atherogenic lipid profiles after 42 months of treatment","volume":"131","author":"Thurberg","year":"2020","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgmr.2026.101293_bb0190","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1007\/s10545-017-0123-6","article-title":"Olipudase alfa for treatment of acid sphingomyelinase deficiency (ASMD): safety and efficacy in adults treated for 30 months","volume":"41","author":"Wasserstein","year":"2018","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgmr.2026.101293_bb0195","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s13023-023-02700-x","article-title":"Olipudase alfa enzyme replacement therapy for acid sphingomyelinase deficiency (ASMD): sustained improvements in clinical outcomes after 6.5 years of treatment in adults","volume":"18","author":"Lachmann","year":"2023","journal-title":"Orphanet J. Rare Dis."}],"container-title":["Molecular Genetics and Metabolism Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214426926000054?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214426926000054?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T22:42:49Z","timestamp":1773355369000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2214426926000054"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":39,"alternative-id":["S2214426926000054"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgmr.2026.101293","relation":{},"ISSN":["2214-4269"],"issn-type":[{"value":"2214-4269","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Olipudase alfa treatment for pediatric acid sphingomyelinase deficiency in Egypt: A prospective, observational cohort study with an interventional subgroup","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgmr.2026.101293","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101293"}}